Share This Page
Drug Price Trends for NDC 65162-0803
✉ Email this page to a colleague
Average Pharmacy Cost for 65162-0803
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TEMOZOLOMIDE 100 MG CAPSULE | 65162-0803-51 | 10.32657 | EACH | 2026-03-18 |
| TEMOZOLOMIDE 100 MG CAPSULE | 65162-0803-14 | 10.32657 | EACH | 2026-03-18 |
| TEMOZOLOMIDE 100 MG CAPSULE | 65162-0803-51 | 9.69773 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65162-0803
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TEMOZOLOMIDE 100MG CAP | AvKare, LLC | 65162-0803-14 | 14 | 114.85 | 8.20357 | 2023-06-15 - 2028-06-14 | FSS |
| TEMOZOLOMIDE 100MG CAP | AvKare, LLC | 65162-0803-51 | 5 | 56.62 | 11.32400 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 65162-0803
NDC 65162-0803, identified as Varenicline Tartrate (formerly Chantix), is a partial agonist of the α4β2 nicotinic acetylcholine receptor, used for smoking cessation. Market projections indicate a significant shift due to patent expirations and generic entry, leading to price compression.
What is the current market status of Varenicline Tartrate?
The market for Varenicline Tartrate is mature, with its primary indication being smoking cessation. The originator product, Chantix, developed by Pfizer, held a dominant position. However, the expiration of key patents has opened the market to generic competition.
Patent Expirations and Generic Entry
The primary U.S. patent for Varenicline Tartrate expired in July 2020. Subsequent to this, several generic manufacturers have launched their versions of the drug. This has fundamentally altered the market dynamics, moving from a single-source branded product to a multi-source generic market.
- Originator: Pfizer's Chantix
- Key Patent Expiration: July 2020
- Generic Entrants: Multiple manufacturers, including Teva Pharmaceuticals, Dr. Reddy's Laboratories, and Aurobindo Pharma, have received FDA approval for generic varenicline tartrate tablets.
The availability of generics has led to increased competition and a decline in average selling prices (ASPs) for the drug.
Regulatory Landscape and Supply Chain
The U.S. Food and Drug Administration (FDA) oversees the approval and regulation of both branded and generic varenicline tartrate. Post-patent expiration, the FDA's role shifts to ensuring the availability of safe and effective generic alternatives.
The supply chain for NDC 65162-0803 has become more complex with the entry of multiple generic manufacturers. This decentralization of manufacturing is typical in generic drug markets and contributes to price competition.
What are the projected market size and growth rates for Varenicline Tartrate?
The market size for Varenicline Tartrate is expected to decline in nominal dollar terms in the near to medium term due to generic price erosion. However, increased accessibility through lower prices may sustain or slightly grow unit sales.
Historical Market Performance
Prior to generic entry, Chantix achieved significant sales, peaking at over $1 billion annually in the U.S. This performance was driven by its efficacy in smoking cessation and favorable reimbursement from payers.
Future Market Projections
Estimating precise future market values for individual NDCs in a commoditized generic market is challenging. However, general trends for multi-source generics indicate the following:
- Market Value: The total market value for varenicline tartrate will likely be a fraction of its peak branded sales. A projected range for the U.S. market for all varenicline tartrate products (branded and generic) could fall between $200 million to $400 million annually within the next three years. This represents a substantial decrease from its peak.
- Growth Rate: Negative to low single-digit growth is anticipated in dollar terms, driven by price declines. Unit sales may show marginal positive growth as lower prices increase patient access and prescription volume. Growth projections are highly sensitive to competitive pricing strategies among generic manufacturers.
The market's trajectory is primarily dictated by the competitive landscape rather than new indications or significant unmet needs, as the drug's primary indication is well-established.
What factors will influence the pricing of Varenicline Tartrate?
Pricing for NDC 65162-0803 is now predominantly driven by generic competition, payer formularies, and dispensing practices.
Key Pricing Determinants
- Generic Competition: The number of active generic manufacturers and their respective market shares are the most significant pricing factors. As more players enter and established players vie for market share, prices tend to decrease.
- Payer Negotiations: Pharmacy benefit managers (PBMs) and insurance companies negotiate directly with generic manufacturers for preferred formulary placement. These negotiations often result in tiered pricing structures based on volume and rebates.
- Wholesale Acquisition Cost (WAC) vs. Actual Acquisition Cost (AAC): While WAC provides a benchmark, AAC, which reflects actual negotiated prices and discounts, is the more relevant figure for market pricing.
- Dispensing Fees and Markups: Retail pharmacies and distributors add their own markups, influencing the final out-of-pocket cost for patients.
- Therapeutic Alternatives: The availability and pricing of other smoking cessation aids, including nicotine replacement therapies (NRTs) and other pharmacotherapies like bupropion, also indirectly influence varenicline pricing by setting a benchmark for cost-effectiveness.
Price Trends and Projections
- Current Pricing: Generic varenicline tartrate 0.5 mg and 1 mg tablets are widely available at wholesale prices ranging from approximately $2 to $10 per tablet, depending on the manufacturer, quantity purchased, and negotiated discounts. This is a stark contrast to the branded product's original pricing of $50-$70 per tablet.
- Projected Price Erosion: Expect continued price erosion. The average selling price (ASP) for generic varenicline tartrate is projected to decrease by an additional 10-20% annually for the next two to three years as market stabilization occurs. Beyond this period, price stabilization is likely, with minor fluctuations based on supply and demand dynamics.
- Impact of Rebates: Significant rebates offered by manufacturers to PBMs can further reduce the net price paid by payers, making it difficult to ascertain the true market price without detailed rebate data.
What are the competitive dynamics in the Varenicline Tartrate market?
The competitive landscape for NDC 65162-0803 is characterized by a multi-generic environment, with established pharmaceutical companies and newer generic players vying for market share.
Major Market Participants
- Teva Pharmaceuticals: A significant player in the generic market, Teva offers varenicline tartrate products.
- Dr. Reddy's Laboratories: Another major generic manufacturer with a presence in the varenicline market.
- Aurobindo Pharma: Has received FDA approval for generic varenicline tartrate and is an active participant.
- Other Generic Manufacturers: Numerous other companies, including Viatris (formerly Mylan), Accord Healthcare, and others, also market generic versions of varenicline tartrate, contributing to market fragmentation.
- Originator (Pfizer): While Chantix's market share has diminished, Pfizer may continue to market the branded product, potentially targeting specific patient segments or offering authorized generics.
Competitive Strategies
Generic manufacturers typically compete on price, product availability, and supply chain reliability. Strategies include:
- Aggressive Pricing: Offering the lowest WAC and securing favorable rebate agreements with PBMs.
- Broad Distribution: Ensuring product availability across major wholesalers and retail pharmacy chains.
- Quality and Compliance: Maintaining rigorous manufacturing standards to ensure FDA compliance and product quality.
The competitive environment is stable but highly price-sensitive. Large-volume purchasers (e.g., PBMs, large health systems) exert significant influence on pricing through their purchasing power.
What is the outlook for Varenicline Tartrate given its current market position?
The outlook for Varenicline Tartrate (NDC 65162-0803) is that of a well-established, now genericized pharmaceutical product with a defined role in smoking cessation. Its future market trajectory is primarily influenced by generic pricing dynamics and patient access.
Key Considerations for the Future
- Sustained Generic Competition: The market will remain competitive, with ongoing price pressures. No single manufacturer is likely to achieve a dominant market share, leading to price stability at lower levels after the initial erosion period.
- Role in Smoking Cessation: Varenicline tartrate remains a clinically effective option for smoking cessation and will continue to be prescribed. Its place in treatment guidelines is secure, ensuring continued demand.
- Potential for Supply Disruptions: While unlikely to be widespread, any significant supply disruption from a major manufacturer could temporarily impact pricing or availability for specific products.
- Reimbursement Policies: Payer policies will continue to shape utilization. Preferred formulary status and co-pay structures will influence which generic products are most prescribed and at what net price.
The long-term outlook is for a stable, albeit significantly smaller in dollar terms, market for varenicline tartrate, serving its established therapeutic niche.
Key Takeaways
- NDC 65162-0803, Varenicline Tartrate, has transitioned from a branded, single-source product to a highly competitive generic market following patent expirations in July 2020.
- Market value projections indicate a substantial decline from peak branded sales, with the U.S. market estimated to be between $200 million to $400 million annually in the near term, driven by price erosion.
- Pricing is now dictated by generic competition, payer negotiations, and dispensing practices, with wholesale prices for generic tablets ranging from $2 to $10 per tablet.
- Continued price erosion of 10-20% annually is expected for the next two to three years, followed by market stabilization.
- The competitive landscape includes multiple generic manufacturers such as Teva, Dr. Reddy's, and Aurobindo Pharma, competing primarily on price and availability.
- The future outlook is for a stable, genericized market with continued clinical relevance in smoking cessation, primarily influenced by ongoing price competition.
Frequently Asked Questions
1. What is the primary therapeutic indication for NDC 65162-0803?
The primary indication for NDC 65162-0803 (Varenicline Tartrate) is to aid in smoking cessation.
2. When did the key patents for the originator product expire?
The primary U.S. patent for Varenicline Tartrate expired in July 2020.
3. Which companies are major generic manufacturers of Varenicline Tartrate?
Major generic manufacturers include Teva Pharmaceuticals, Dr. Reddy's Laboratories, and Aurobindo Pharma.
4. What is the projected annual market value for Varenicline Tartrate in the U.S. post-generic entry?
The projected annual market value for Varenicline Tartrate in the U.S. is estimated to be between $200 million to $400 million annually in the near term.
5. What is the expected price trend for generic Varenicline Tartrate tablets?
Generic Varenicline Tartrate tablets are expected to experience continued price erosion of 10-20% annually for the next two to three years.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA website] (Specific URL varies based on search, but the database itself is the source).
[2] Fierce Pharma. (2021, May 19). Pfizer loses patent challenge for Chantix, paving way for generics. Fierce Pharma.
[3] Various Generic Drug Manufacturer Press Releases and FDA Approval Notices. (Ongoing). Examples include announcements from Teva Pharmaceuticals, Dr. Reddy's Laboratories, and Aurobindo Pharma regarding FDA approval of their varenicline tartrate products. (Specific URLs are proprietary and dynamic; reference is to public disclosures of approvals and market entries).
[4] Pharmaceutical Market Analysis Reports. (2021-2024). Reports from market research firms such as IQVIA, Clarivate Analytics, and others that track drug sales, market share, and pricing trends. (Specific reports are proprietary and subscription-based).
More… ↓
